Skip to main content
SpringerLink
Log in

Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization

  • CIRSE Standards of Practice Guidelines
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397–401

    PubMed  CAS  Google Scholar 

  2. Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590

    Article  PubMed  CAS  Google Scholar 

  3. Pleguezuelo M, Marelli L, Misseri M et al (2008) TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8(10):1623–1641

    Article  PubMed  CAS  Google Scholar 

  4. Hong K, Khwaja A, Liapi E, et al. (2006) New intra-arterial drug delivery system for the treatment of liver cancer: Preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12(8):2563–2567

    Google Scholar 

  5. Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476

    Article  PubMed  Google Scholar 

  6. Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI), in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multiinstitutional study. Ann Surg Oncol 18(1):192–198

    Article  PubMed  Google Scholar 

  7. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  8. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524

    Article  PubMed  Google Scholar 

  9. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  PubMed  Google Scholar 

  10. Bruix J, Sherman M (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  11. Kothary N, Weintraub JL, Susman J, Rundback JH et al (2007) Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 18(12):1517–1526

    Article  PubMed  Google Scholar 

  12. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1):71–81

    Article  PubMed  Google Scholar 

  13. Berger DH, Carrasco CH, Hohn DC et al (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: posttreatment management and complications. J Surg Oncol 60:116–121

    Article  PubMed  CAS  Google Scholar 

  14. Brown DB, Fundakowski CE, Lisker-Melman M et al (2004) Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 15:1209–1218

    Article  PubMed  Google Scholar 

  15. Liapi E, Geschwind JFH (2011) Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34:37–49

    Article  PubMed  Google Scholar 

  16. Ryan JM, Ryan BM, Smith TP (2004) Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 15:547–556

    Article  PubMed  Google Scholar 

  17. Kim W, Clark TWI, Baum RA et al (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965–968

    Article  PubMed  CAS  Google Scholar 

  18. Geschwind JF, Kaushik S, Ramsey DE et al (2002) Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 13:1163–1166

    Article  PubMed  Google Scholar 

  19. Cheng HY, Shou Y, Wang X et al (2004) Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 10:2753–2755

    PubMed  Google Scholar 

  20. Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–4033

    PubMed  CAS  Google Scholar 

  21. Kim HC, Chung JW, Lee W (2005) Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 25:S25–S39

    Article  PubMed  Google Scholar 

  22. Kwon JW, Chung JW, Song SY et al (2002) Transcatheter arterial chemoembolization for hepatocellular carcinomas in patients with celiac axis occlusion. J Vasc Interv Radiol 13(7):689–694

    Article  PubMed  Google Scholar 

  23. Miyayama S, Yamashiro M, Okuda M et al (2009) Usefulness of cone-beam computed tomography during ultraselective transcatheter arterialchemoembolization for small hepatocellular carcinomas that cannot be showed on angiography. Cardiovasc Intervent Radiol 32(2):255–264

    Article  PubMed  Google Scholar 

  24. Takayasu K, Arii S, Matsuo N et al (2000) Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 175:699–704

    CAS  Google Scholar 

  25. Kubota K, Hisa N, Nishikawa T et al (2001) Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 26:184–190

    Article  PubMed  CAS  Google Scholar 

  26. Chopra S, Dodd GD, Chintapalli KN et al (2001) Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. Am J Roentgenol 177:381–387

    CAS  Google Scholar 

  27. Ernst O, Sergent G, Mizrahi D et al (1999) Treatment of hepatocellular carcinoma by transcatheter arterial chemo-embolization: comparison of planned periodic chemo-embolization and chemo-embolization based on tumor response. Am J Roentgenol 172:59–64

    CAS  Google Scholar 

  28. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60

    Article  PubMed  CAS  Google Scholar 

  29. Oliveri RA, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 16:CD004787

    Google Scholar 

  30. Ray CE, Haskal ZJ, Geschwind GFH et al (2011) The Use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration Review of 2011. J Vasc Interv Radiol 22:1693–1696

    Article  PubMed  Google Scholar 

  31. Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359(9319):1734–1739

    Article  PubMed  Google Scholar 

  32. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  33. Llovet JM, Bruix J, for the Barcelona-Clinic Liver Cancer Group (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 37:429–442

    Article  PubMed  CAS  Google Scholar 

  34. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 30:6–25

    Article  Google Scholar 

  35. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52

    Article  PubMed  Google Scholar 

  36. Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541–551

    Article  PubMed  Google Scholar 

  37. Tellez C, Benson AB III, Lyster MT et al (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250–1259

    Article  PubMed  CAS  Google Scholar 

  38. Vogl TJ, Gruber T, Balzer JO et al (2009) Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 250(1):281–289

    Article  PubMed  Google Scholar 

  39. Aliberti C, Tilli M, Benea G et al (2006) Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res 26(5B):3793–3795

    PubMed  CAS  Google Scholar 

  40. Fiorentini G, Aliberti C, Turrisi G et al (2007) Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21(6):1085–1091

    PubMed  CAS  Google Scholar 

  41. Roche A, Girish BV, de Baère T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 3(1):136–140

    Google Scholar 

  42. de Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855–861

    Article  PubMed  Google Scholar 

  43. Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361

    Article  PubMed  Google Scholar 

  44. Gusani NJ, Balaa FK, Steel JL et al (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12(1):129–137

    Article  PubMed  Google Scholar 

  45. Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 31(5):883–888

    Article  PubMed  Google Scholar 

  46. Poggi G, Amatu A, Montagna B et al (2009) OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32(6):1187–1192

    Article  PubMed  Google Scholar 

  47. Brown DB, Cardella JF, Sacks D et al (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20:S219–S226

    Article  PubMed  Google Scholar 

  48. Sueyoshi E, Hayashida T, Sakamoto I et al (2010) Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 195:245–251

    Article  Google Scholar 

  49. Chan AO, Yuen MF, Hui CK, et al. (2002) A prospective study regarding the complications of transcatheter intra-arterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94(6):1747–1752

    Google Scholar 

  50. Group d’Etude et de Treatment du Carcinoma Hepatocellulaire (1995) A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Ospedale Garibaldi Centro, Piazza Santa Maria del Gesù, 95124, Catania, Italy

    Antonio Basile

  2. Department of Radiology, Insubria University, 21100, Varese, Italy

    Gianpaolo Carrafiello & Anna Maria Ierardi

  3. Department of Radiology, Medical School of Crete, University Hospital of Heraklion, P. O. Box 1352, Stavrakia, 71110, Heraklion, Crete, Greece

    Dimitrios Tsetis

  4. Department of Radiology, Athens University Medical School, Attikon University Hospital, 1 Rimini St., 12462, Chaidari, Greece

    Elias Brountzos

Authors
  1. Antonio Basile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianpaolo Carrafiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Maria Ierardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitrios Tsetis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elias Brountzos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Basile.

Appendix 1

Appendix 1

Minor Complications

  1. A.

    No therapy and no consequences.

  2. B.

    Nominal therapy and no consequences; includes overnight admission for observation only.

Major Complications

  1. C.

    Require therapy and minor hospitalization (<48 h).

  2. D.

    Require major therapy, unplanned increase in level of care, and prolonged hospitalization (>48 h).

  3. E.

    Permanent adverse.

  4. F.

    Death.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basile, A., Carrafiello, G., Ierardi, A.M. et al. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. Cardiovasc Intervent Radiol 35, 765–774 (2012). https://doi.org/10.1007/s00270-012-0423-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-012-0423-z

Keywords

Search

Navigation